{
  "id": "5e4b52e36d0a27794100001b",
  "type": "list",
  "question": "Which drugs are included in the drug LONSURF?",
  "ideal_answer": "Lonsurf includes trifluridine and tipiracil. It is a novel oral anti-tumor agent combining an anti-neoplastic thymidine-based nucleoside analogue (trifluridine) with a thymidine phosphorylase inhibitor (tipiracil hydrochloride) presents a new treatment option for metastatic colorectal cancer patients refractory or intolerant to standard therapies.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/28315543",
    "http://www.ncbi.nlm.nih.gov/pubmed/31002008",
    "http://www.ncbi.nlm.nih.gov/pubmed/29177842",
    "http://www.ncbi.nlm.nih.gov/pubmed/28213365",
    "http://www.ncbi.nlm.nih.gov/pubmed/26609205",
    "http://www.ncbi.nlm.nih.gov/pubmed/30445951",
    "http://www.ncbi.nlm.nih.gov/pubmed/27431756",
    "http://www.ncbi.nlm.nih.gov/pubmed/26197742",
    "http://www.ncbi.nlm.nih.gov/pubmed/30350179",
    "http://www.ncbi.nlm.nih.gov/pubmed/31489588",
    "http://www.ncbi.nlm.nih.gov/pubmed/27568360",
    "http://www.ncbi.nlm.nih.gov/pubmed/28977993"
  ],
  "snippets": [
    {
      "text": "The National Institute for Health and Care Excellence (NICE) invited Servier, the company manufacturing trifluridine and tipiracil (T/T; trade name: Lonsurf\u00ae), to submit evidence for the clinical and cost effectiveness of T/T compared with best supportive care (BSC) for metastatic colorectal cancer (third-line or later).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29177842",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "PURPOSE: Trifluridine/tipiracil (FTD/TPI; TAS-102, Lonsurf\u00ae), a novel form of chemotherapy for metastatic colorectal cancer (mCRC), has shown clinical benefit in the global, phase III RECOURSE trial, regardless of patient age. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30350179",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: Trifluridine/tipiracil (TAS-102, Lonsurf\u00ae), a novel oral anti-tumor agent combining an anti-neoplastic thymidine-based nucleoside analogue (trifluridine, FTD) with a thymidine phosphorylase inhibitor (tipiracil hydrochloride, TPI) presents a new treatment option for metastatic colorectal cancer (mCRC) patients refractory or intolerant to standard therapies. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30445951",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "These AEs may affect patient adherence, particularly with completely oral regimens, such as trifluridine/tipiracil (TAS-102, Lonsurf\u00ae), an antimetabolite agent for patients with mCRC refractory or intolerant to standard therapies.\u2029",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28315543",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The FDA approved TAS-102 (Lonsurf; Taiho Oncology, Inc.) for the treatment of patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy; an anti-VEGF biological therapy; and if RAS wild type, an anti-EGFR therapy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28213365",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Here we show that tumoroid cultures from a CRC patient are highly sensitive to the thymidylate synthase inhibitor 5-fluorouracil (adrucil) but less sensitive to the combination of nucleoside analog trifluridine and thymidine phosphorylase inhibitor tipiracil (Lonsurf).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28977993",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Trifluridine/tipiracil (Lonsurf(\u00ae)) is a novel, orally active, antimetabolite agent comprised of trifluridine, a thymidine-based nucleoside analogue, and tipiracil, a potent thymidine phosphorylase inhibitor.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27568360",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "TAS-102 (Lonsurf) is an oral fluoropyrimidine that is formed by the combination of 2 active drugs: trifluridine (a nucleoside analog) and tipiracil hydrochloride (a thymidine phosphorylase inhibitor).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27431756",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Trifluridine/tipiracil (Lonsurf __sup__ \u00ae __end_sup__ ) is a fixed-dose combination tablet comprising trifluridine, an antineoplastic nucleoside analogue, and tipiracil, a thymidine phosphorylase inhibitor.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31489588",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The National Institute for Health and Care Excellence (NICE) invited Servier, the company manufacturing trifluridine and tipiracil (T/T; trade name: Lonsurf __sup__ \u00ae __end_sup__ ), to submit evidence for the clinical and cost effectiveness of T/T compared with best supportive care (BSC) for metastatic colorectal cancer (third-line or later).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29177842",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Here we show that tumoroid cultures from a CRC patient are highly sensitive to the thymidylate synthase inhibitor 5-fluorouracil (adrucil) but less sensitive to the combination of nucleoside analog trifluridine and thymidine phosphorylase inhibitor tipiracil (Lonsurf).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28977993",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Trifluridine/tipiracil (Lonsurf \u00ae ) is a fixed-dose combination tablet comprising trifluridine, an antineoplastic nucleoside analogue, and tipiracil, a thymidine phosphorylase inhibitor.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31489588",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "What is already known TAS 102 (Lonsurf) is an oral fixed dose combination of trifluridine (FTD) and tipiracil (TPI) indicated as salvage-line treatment in patients with therapy refractory metastatic colorectal cancer (mCRC).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31002008",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "What is already known TAS 102 (Lonsurf) is an oral fixed dose combination of trifluridine (FTD) and tipiracil (TPI) indicated as salvage-line treatment in patients with therapy refractory metastatic colorectal cancer (mCRC).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31002008",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Evolocumab (Repatha) for patients with hypercholesterolemia whose condition has not been controlled by statins and other therapies; trifluridine/tipiracil (Lonsurf) for metastatic colorectal cancer; and blood coagulation factor VIII (Nuwiq) for adults and children with hemophilia A.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26609205",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In May 2014 , tablets containing both trifluridine and tipiracil hydrochloride ( Lonsurf\u00ae tablets ) were launched in Japan ahead of other countries , for the treatment of advanced/relapsed unresectable colorectal cancer . ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26197742",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Trifluridine/tipiracil ( TAS-102 , Lonsurf\u00ae) , a novel oral anti-tumor agent combining an anti-neoplastic thymidine-based nucleoside analogue ( trifluridine , FTD ) with a thymidine phosphorylase inhibitor ( tipiracil hydrochloride , TPI ) presents a new treatment option for metastatic colorectal cancer ( mCRC ) patients refractory or intolerant to standard therapies . ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30445951",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Evolocumab ( Repatha ) for patients with hypercholesterolemia whose condition has not been controlled by statins and other therapies; trifluridine/tipiracil ( Lonsurf ) for metastatic colorectal cancer; and blood coagulation factor VIII ( Nuwiq ) for adults and children with hemophilia A .",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26609205",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Trifluridine/tipiracil ( Lonsurf(\u00ae) ) is a novel , orally active , antimetabolite agent comprised of trifluridine , a thymidine-based nucleoside analogue , and tipiracil , a potent thymidine phosphorylase inhibitor . ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27568360",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The National Institute for Health and Care Excellence ( NICE ) invited Servier , the company manufacturing trifluridine and tipiracil ( T/T; trade name: Lonsurf) , to submit evidence for the clinical and cost effectiveness of T/T compared with best supportive care ( BSC ) for metastatic colorectal cancer ( third-line or later) . ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29177842",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Trifluridine/tipiracil ( Lonsurf ) is a fixed-dose combination tablet comprising trifluridine , an antineoplastic nucleoside analogue , and tipiracil , a thymidine phosphorylase inhibitor . ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31489588",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "TAS-102 ( Lonsurf ) is an oral fluoropyrimidine that is formed by the combination of 2 active drugs: trifluridine ( a nucleoside analog ) and tipiracil hydrochloride ( a thymidine phosphorylase inhibitor) . ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27431756",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "These AEs may affect patient adherence , particularly with completely oral regimens , such as trifluridine/tipiracil ( TAS-102 , Lonsurf\u00ae) , an antimetabolite agent for patients with mCRC refractory or intolerant to standard therapies . .",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28315543",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Trifluridine/tipiracil ( FTD/TPI; TAS-102 , Lonsurf\u00ae) , a novel form of chemotherapy for metastatic colorectal cancer ( mCRC) , has shown clinical benefit in the global , phase III RECOURSE trial , regardless of patient age. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30350179",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "TAS-102 (Lonsurf) is an oral fluoropyrimidine that is formed by the combination of 2 active drugs: trifluridine (a nucleoside analog) and tipiracil hydrochloride (a thymidine phosphorylase inhibitor).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27431756",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND\nTrifluridine/tipiracil (TAS-102, Lonsurf\u00ae), a novel oral anti-tumor agent combining an anti-neoplastic thymidine-based nucleoside analogue (trifluridine, FTD) with a thymidine phosphorylase inhibitor (tipiracil hydrochloride, TPI) presents a new treatment option for metastatic colorectal cancer (mCRC) patients refractory or intolerant to standard therapies.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30445951",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In May 2014, tablets containing both trifluridine and tipiracil hydrochloride (Lonsurf\u00ae tablets) were launched in Japan ahead of other countries, for the treatment of advanced/relapsed unresectable colorectal cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26197742",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In May 2014, tablets containing both trifluridine and tipiracil hydrochloride (Lonsurf\u00ae tablets) were launched in Japan ahead of other countries, for the treatment of advanced/relapsed unresectable colorectal cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26197742",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: Trifluridine/tipiracil (TAS-102, Lonsurf\u00ae), a novel oral anti-tumor agent combining an anti-neoplastic thymidine-based nucleoside analogue (trifluridine, FTD) with a thymidine phosphorylase inhibitor (tipiracil hydrochloride, TPI) presents a new treatment option for metastatic colorectal cancer (mCRC) patients refractory or intolerant to standard therapies.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30445951",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Trifluridine/tipiracil (Lonsurf",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31489588",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Trifluridine/tipiracil (TAS-102, Lonsurf\u00ae), a novel oral anti-tumor agent combining an anti-neoplastic thymidine-based nucleoside analogue (trifluridine, FTD) with a thymidine phosphorylase inhibitor (tipiracil hydrochloride, TPI) presents a new treatment option for metastatic colorectal cancer (mCRC) patients refractory or intolerant to standard therapies.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30445951",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "trifluridine, tipiracil"
}